Unlocking the Future of Immunotherapy with Hybridoma Technology - Video

Published On 2024-03-15T11:35:06+05:30 | Updated On 20 March 2024 12:34 PM IST

Overview

Hybridoma technology is used in treatment of autoimmune conditions, viral infections and cancer, states a recent narrative review in the American Journal of Biopharmacy and Pharmatceutical Sciences published by Scientific Scholar. The importance of immunotherapeutics based on antibody and hybridoma technologies is revolutionizing the treatment environment and creating new opportunities for customized and targeted therapies.

A focused and extremely specific treatments for a wide range of ailments, including cancer, autoimmune disorders, and infectious diseases, immunotherapeutics based on antibody and hybridoma technologies have completely changed the practice of medicine.

By harnessing the immune system’s strength and fusing it with cutting-edge biotechnology, this method creates monoclonal antibodies (mAbs), which are therapeutic agents that mAbs are molecules created in a laboratory that resembles the immune system’s naturally occurring antibodies.

This research offers a thorough analysis of immunotherapeutics with a focus on hybridomas. It describes how focused and precise treatments for a variety of illnesses, such as cancer, autoimmune disorders, and infectious diseases, have been made possible by immunotherapeutics, which are based on antibody and hybridoma technology.

The hybridoma technology process, is a heterogeneous population of cells that produce unique mAbs are created by combining immortalized myeloma cells with B lymphocytes. To isolate and create drug formulations, the hybridoma cells that produce the desired antibodies are chosen and grown in large numbers.

Reference: Vaghela AR, Ganatra TH. A detailed review of immunotherapeutics with a special emphasis on hybridoma technology. Am J Biopharm Pharm Sci. 2024;4:2. doi: 10.25259/AJBPS_13_2023

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751